VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$26.86+5.91%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put VKTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskVKTX’s case rests on advancing VK2735 through Phase 3 obesity trials, not current earnings. Revenue growth cannot be assessed from the desk, and third-quarter 2026 earnings missed. The desk has no clean valuation multiple, so peer multiples cannot define the price. The price is roughly in line with the growth forecast, though the next-quarter miss probability is 57%. The specific risk is another earnings miss amid rising research and development spending. Peer multiples imply a price about 71% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-29. VKTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering VKTX (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare VKTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VKTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put VKTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Phase 3 clinical development of VK2735 for obesity
Pivotal Phase 3 initiation advances VK2735 obesity development despite prior Phase 2 disappointment.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance Phase 3 clinical development of VK2735 for obesity
Positive data boosts confidence in VK2735's Phase 3 development.
Advances: Maintain fiscal discipline amid increased R&D spending
Funding supports R&D and fiscal discipline amid increased spending.
Advances: Advance VK2735 maintenance dosing study and report data in Q3 2026
New growth driver aligns with VK2735 maintenance dosing study.
Threatens: Advance Phase 3 clinical development of VK2735 for obesity
Caution on VK2735 results may hinder Phase 3 development.
Threatens: Maintain fiscal discipline amid increased R&D spending
Increased R&D spending may strain fiscal discipline.
Advances: Advance Phase 3 clinical development of VK2735 for obesity
Positive trial results support VK2735's development for obesity.
Threatens: Maintain fiscal discipline amid increased R&D spending
Increased R&D spending may strain fiscal discipline.
